Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STABILIZE-CKD: SZC to prevent CKD progression in patients with or at risk of hyperkalaemia
jRCT2031210441Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and hyperkalemia comparing SZC maintenance with Placebo maintenance (2 arms). Primary endpoints: Total eGFR slope and Chronic eGFR slope. Started Jan 2022; status: active, not recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
chronic kidney disease (CKD)hyperkalemia
Beyond the preview
Go deeper on jRCT2031210441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210441.